Spada Serena, Cuccu Antonella, Mussap Michele, Testa Marcella, Puddu Melania, Pisu Cinzia, Burrai Pietrina, Fanos Vassilios
Neonatal Pathology and Intensive Therapy, University of Cagliari, Italy.
J Matern Fetal Neonatal Med. 2009;22 Suppl 3:96-101. doi: 10.1080/14767050903195450.
Procalcitonin (PCT) has been proposed as an interesting marker in the diagnosis, prognosis, and response to treatment of patient with neonatal sepsis. Fifty-nine neonates (34 males and 25 females) with a mean gestational age of approximately 31 weeks and a mean weight of about 1750 g admitted in the Neonatal Intensive Care Unit of Cagliari (Italy) were evaluated in controls and in infected neonates, before and after 48 h of life. From our experience it emerges that PCT is a marker of early and late neonatal sepsis which is reliable in preterm neonates. A cut-off of 0.5 ng/ml starting from the third day of life appears to be capable of ensuring good test sensitivity and specificity.
降钙素原（PCT）已被提议作为诊断、预测及治疗新生儿败血症患者的一项重要指标。对入住意大利卡利亚里新生儿重症监护病房的59例新生儿（34例男性，25例女性）进行了评估，这些新生儿平均胎龄约31周，平均体重约1750克，分别在出生后48小时内及之后作为对照组和感染组进行观察。根据我们的经验，PCT是新生儿早发性和晚发性败血症的可靠指标，对早产儿同样适用。从出生第三天起，以0.5 ng/ml作为临界值似乎能够确保良好的检测灵敏度和特异性。
